Skip to main content

NCI at AACR COVID-19 and Cancer Virtual Meeting

The National Cancer Institute (NCI) is participating in the American Association for Cancer Research (AACR) COVID-19 and Cancer Virtual Meeting, July 20-22, 2020.

The AACR COVID-19 and Cancer Meeting will share the emerging data in basic, clinical, and epidemiologic research related to COVID-19 and cancer. The program features presentations from NCI leaders and experts. These presentations will cover COVID-19 treatment candidates, diagnostics development, cancer drug repurposing, clinical trial changes during the pandemic, and NCI’s role in ensuring cancer research progress. Registration is now available.

Subscribe for the latest information on presentations and resources from NCI at AACR 2020 and future meetings.

NCI Director

NCI Director, Ned. Sharpless, MD participated in a roundtable discussion, entitled “Returning to Cancer Research During COVID-19,” during the closing session of the AACR meeting. His presentation, “NCI’s Role in Ensuring Cancer Research Progress Amid a Pandemic,” highlighted how NCI has contributed scientific expertise to this public health crisis. He shared NCI’s efforts to quickly understand and navigate the impacts of COVID-19, particularly for cancer patients, which includes providing a variety of flexibilities in clinical trial operations. In addition, Dr. Sharpless presented the immediate effects that the pandemic is having on cancer research, as well as described concerns about the potential effects on longer-term cancer outcomes.


Additional Presentations Featuring NCI Leaders and Experts

Douglas R. Lowy, M.D.

NCI principal deputy director, Dr. Doug Lowy, presented, “When Cancer Research Goes Viral,” during the COVID-19 and Diagnostics Development Symposium. Dr. Lowy discussed how NCI has responded to the COVID-19 pandemic through research at the Frederick National Laboratory, development of a serology network (SeroNet), developing a COVID-19 natural history study in patients with cancer (NCCAPS), and tracking SARS-CoV-2 seroprevalence. In addition, he discussed how the COVID-19 pandemic may stimulate modified approaches to cancer screening moving forward.

James H. Doroshow, M.D.

NCI Deputy Director and Director of NCI’s Division of Cancer Treatment and Diagnosis, Dr. Jim Doroshow, participated in the Forum on Regulatory and Operational Implications of Cancer Clinical Trial Changes During COVID-19.

Louis M. Staudt, Ph.D.

Cancer researcher and Director of NCI’s Center for Cancer Genomics, Dr. Staudt, presented his session, “Inhibition of Bruton Tyrosine Kinase in patients with severe COVID-19,” during the Symposium on Cancer Drug Repurposing to Treat COVID-19. Dr. Staudt’s presentation described the hyperinflammatory state that occurs in a subset of patients with COVID-19, and how the approved off-label use of BTK inhibitor, Acalabrutinib, is being studied and used to help treat these patients.


Funding Notices for COVID-19

NCI is providing funding for research on COVID-19 and revising some existing grants and cooperative agreements to make funds available to help address the public health crisis. For more information, see NCI Funding Announcements and Notices for COVID-19.

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “NCI at AACR COVID-19 and Cancer Virtual Meeting was originally published by the National Cancer Institute.”